

# Administrative Bulletin 20-88

**101 CMR 320.00: Clinical Laboratory Services**

Effective on dates found in table below.

**Procedure Code Update**

Pursuant to 101 CMR 320.01(3): *Coding Updates and Corrections*, the Executive Office of Health and Human Services (EOHHS) is adding new procedure codes for clinical laboratory services relating to testing for Coronavirus Disease 2019 (COVID-19). As set forth in 101 CMR 320.01(3)(c), rates for newly added codes are calculated according to the rate methodology used in setting clinical laboratory rates. Added codes without Medicare fees are reimbursed at individual consideration (I.C.). The rate listed in this administrative bulletin is applicable until revised rates are issued by the EOHHS.

The following table includes the added codes, rates, descriptions and effective dates:

| **Code** | **Rate** | **Description** | **Effective Dates of Service On or After** |
| --- | --- | --- | --- |
| 86408 | I.C. | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen | 08/10/2020 |
| 86409 | I.C. | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer | 08/10/2020 |
| 86413 | I.C. | Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) antibody,quantitative | 09/08/2020 |
| 87636 | I.C. | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique | 10/07/2020 |
| 87637 | I.C. | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique | 10/07/2020 |
| 87811 | I.C. | Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) | 10/07/2020 |